Legumain Antibody (B-8): sc-133234

Legumain Antibody (B-8) is a mouse monoclonal IgG1 kappa light chain antibody that detects Legumain protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-Legumain antibody (B-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Legumain, also known as LGMN, AEP (asparaginyl endopeptidase), or PRSC1, is a 433 amino acid protein primarily localized to lysosomes, where Legumain plays a crucial role in protein degradation and processing. Such lysosomal localization enables Legumain to participate in hydrolyzing asparaginyl and aspartyl bonds, essential for proper antigen presentation via MHC class II molecules in immune responses. Legumain is expressed ubiquitously, with particularly high levels in placenta, heart, and kidney, existing in both precursor and mature forms, with mature forms produced in dendritic cells. Legumain overexpression has been linked to solid tumor development, suggesting involvement in carcinogenesis. Multiple Legumain isoforms arise from alternative splicing, contributing to diverse functional roles in cellular processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Legumain Antibody (B-8) References:

1. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo.  |  Li, DN., et al. 2003. J Biol Chem. 278: 38980-90. PMID: 12860980
2. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes.  |  Burster, T., et al. 2004. J Immunol. 172: 5495-503. PMID: 15100291
3. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer.  |  Murthy, RV., et al. 2005. Clin Cancer Res. 11: 2293-9. PMID: 15788679
4. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase.  |  Liu, Z., et al. 2008. Mol Cell. 29: 665-78. PMID: 18374643
5. Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.  |  Brix, K., et al. 2015. Protoplasma. 252: 755-74. PMID: 25398648
6. Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.  |  Zhen, Y., et al. 2015. Sci Rep. 5: 16599. PMID: 26607955
7. Targeting Legumain As a Novel Therapeutic Strategy in Cancers.  |  Mai, CW., et al. 2017. Curr Drug Targets. 18: 1259-1268. PMID: 27993111
8. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy.  |  Wang, D., et al. 2018. Kidney Int. 94: 91-101. PMID: 29656902
9. Legumain-mediated self-assembly of a 131I-labelled agent for targeted radiotherapy of tumors.  |  Wang, Q., et al. 2022. J Mater Chem B. 10: 2251-2259. PMID: 35297450
10. Active legumain promotes invasion and migration of neuroblastoma by regulating epithelial-mesenchymal transition.  |  Zhang, M., et al. 2022. Open Life Sci. 17: 676-685. PMID: 35800070
11. Molecular cloning of a human cDNA encoding putative cysteine protease (PRSC1) and its chromosome assignment to 14q32.1.  |  Tanaka, T., et al. 1996. Cytogenet Cell Genet. 74: 120-3. PMID: 8893817
12. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase.  |  Chen, JM., et al. 1997. J Biol Chem. 272: 8090-8. PMID: 9065484

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Legumain Antibody (B-8) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-Legumain Antibody (B-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Legumain Antibody (B-8) Specifications

Alternate Product Name: Legumain

Product Clone Name: B-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 21-320

Epitope Target: Legumain

Epitope Species: human

Product Reactivity/Detection: precursor and mature Legumain

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for Legumain Antibody (B-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin